Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5044 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-01

Study Completion Date

2021-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

NCT04554992

Covid19

UNKNOWN PHASE1

Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease

NCT04542967

Severe COVID-19 Disease

COMPLETED PHASE2

Convalescent Plasma as a Possible Treatment for COVID-19

NCT04442191

COVID-19

RECRUITING PHASE2

Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

NCT04513158

Covid19

TERMINATED PHASE2

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

NCT04374565

Corona Virus Infection SARS-CoV 2 SARS Pneumonia +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The convalescent plasma (CP) of individuals who have recovered from COVID-19 may help reduce symptoms and mortality when given to ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical trials are needed to provide definitive evidence of the benefits and harms of CP in the treatment of COVID-19. While clinical trials are underway, observational research plays a critical role in providing preliminary scientific evidence to guide clinical practice.

This observational study aims to estimate the association between CP therapy and mortality after 30 days in a sample of SARS-CoV-2-positive patients with non-severe illness. Patients include those hospitalized at a facility within the Veterans Health Administration (VHA) of the Department of Veterans Affairs (VA), the largest integrated healthcare system in the United States. Using VA electronic health record data, the study is designed to emulate a target trial of convalescent plasma transfusion and mortality. The primary exposure of interest is the use or non-use of COVID-19 convalescent plasma, and the primary outcome is 30-day all-cause mortality.

A nested trial design will be used, in which patients will be followed from each day in which eligibility criteria are met (while hospitalized and after date of first positive SARS-CoV-2 test) for 30 days. The association between CP therapy and mortality will be assessed using pooled logistic models to estimate 30-day cumulative incidence curves, risk differences, and hazard ratios. Inverse probability weighting derived from propensity scores will be employed to minimize confounding by indication and other biases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Disease 2019 (COVID-19)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exposed

Veterans who received COVID-19 convalescent plasma therapy within 2 days of eligibility

COVID-19 convalescent plasma

Intervention Type BIOLOGICAL

Convalescent plasma collected from individuals who have recovered from COVID-19

Unexposed

Veterans who did not receive COVID-19 convalescent plasma therapy

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19 convalescent plasma

Convalescent plasma collected from individuals who have recovered from COVID-19

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* US Veterans aged 21-80 years old
* Hospitalized between May 1, 2020 and November 17, 2020 with a SARS-CoV-2 positive test, at a VA Medical Center where convalescent plasma had been administered to at least one patient and remained a current practice at that VA Medical Center
* SARS-CoV-2 positive test within 7 days before or after hospital admission
* Minimum oxygen saturation (measured within the past day) \>=90%
* Vitals (pulse, respiration, temperature, systolic blood pressure) and acute labs (hemoglobin, platelet, white blood cells) measured within the past 2 days
* Albumin, Alanine Aminotransferase (ALT), creatinine measured within the past 30 days
* Weight measurement recorded in the past 2 years

Exclusion Criteria

* Prior intubation, ventilation, high flow oxygen, extracorporeal membrane oxygenation (ECMO), dialysis, or vasopressors during current hospitalization
* Record of prior treatment with CP
* Received long-term care in a domiciliary or nursing home in the past 90 days
* First CP recipient at a site
* Less than 30 days of follow-up

Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No